

INTROGEN THERAPEUTICS INC

Form 8-K

December 10, 2004

**Table of Contents**

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 10, 2004 (December 9, 2004)

Introgen Therapeutics, Inc.

---

(Exact name of registrant as specified in its charter)

Delaware

0-21291

74-2704230

---

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(IRS Employer  
Identification No.)

301 Congress Avenue, Suite 1850, Austin, Texas

78701

---

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: (512) 708-9310

---

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**TABLE OF CONTENTS**

Item 8.01. Other Events.

Item 9.01. Financial Statements and Exhibits.

SIGNATURES

INDEX TO EXHIBITS

Press Release

---

**Table of Contents**

**Item 8.01. Other Events.**

On December 9, 2004, Introgen Therapeutics, Inc. (the Company ) issued a press release announcing data from a Phase 2 clinical trial of ADVEXIN therapy, the Company s lead product candidate. The press release is being filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein.

Neither the filing of any press release as an exhibit to this Current Report on Form 8-K nor the inclusion in such press release of a reference to the Company s Internet address shall, under any circumstances, be deemed to incorporate the information available at such Internet address into this Current Report on Form 8-K. The information available at the Company s Internet address is not part of this Current Report on Form 8-K or any other report filed by the Company with the Securities and Exchange Commission.

**Item 9.01. Financial Statements and Exhibits.**

(c) Exhibits.

99.1 Press Release dated December 9, 2004.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 10, 2004

INTROGEN THERAPEUTICS, INC.

/s/ James W. Albrecht, Jr.  
James W. Albrecht, Jr.  
Chief Financial Officer

-3-

---

**Table of Contents**

INDEX TO EXHIBITS

<b>Exhibit Number</b>	<b>Description of Document</b>
99.1	Press Release dated December 9, 2004.